New Drug Granted Orphan Drug Status to Treat Malignant Mesothelioma
CanBas Co., a Japanese-based clinical-stage pharmaceutical company was recently granted orphan drug status by the United States Food and Drug Administration for a new drug that treats advanced malignant pleural mesothelioma, pharmabiz.com reports. Treating mesothelioma is difficult because there is no known cure for this particularly aggressive form of cancer. While pharmacists, scientists and researchers attempt to find […]
